Martin Shkreli, who is serving seven years in prison for securities fraud, has been placed in solitary confinement following a report that he was still running the drug company he helped found from behind bars.
According to a Wall Street Journal report from last month, the disgraced pharmaceutical executive was using a contraband phone to remain involved in the day-to-day operations of Phoenixus AG (formerly Turing Pharmaceuticals).
Shkreli, known for raising the price of a potentially life-saving drug by 5,000 percent, was brought to the special housing unit (SHU) at Fort Dix about 10 days after the WSJ report, according to Forbes.
The Bureau of Prisons has not confirmed Shkreli is currently in solitary confinement, but did say he was “under investigation” following the WSJ report.
“When there are allegations of misconduct, they are thoroughly investigated, and appropriate action is taken if allegations are sustained,” a BOP spokesperson said.
Even if he is in solitary, it could be worth it for Shkreli, 36.
In the Journal’s initial report, the publication said that if Phoenixus continues to grow at its current pace under the “Pharma Bro’s” stewardship, it could be worth $3.7 billion by the time he is set free from prison in 2023.
Thanks for reading InsideHook. Sign up for our daily newsletter and be in the know.